Black Diamond Therapeutics Inc (BDTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.95 (+1.04%), Market cap $0.21B, 52-week low–high $1.99 ~ $4.87.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4
Financial statements, price targets, institutional (13F) holdings and related news for Black Diamond Therapeutics Inc are updated in real time on BlackAll Trade.
Black Diamond Therapeutics Inc trades at $1.95 (+1.04%). Real-time quotes and charts are available on BlackAll Trade.
Black Diamond Therapeutics Inc has a market cap of about $0.21B.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead pr